Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business

Genenta Science SPA (NASDAQ:GNTA) is among the best Italian stocks to buy in 2026. Genenta Science SPA (NASDAQ:GNTA) will hold an extraordinary shareholders meeting on March 26. This comes on the back of the company announcing a major shift in its business strategy.

Genenta Science, which has all along been concentrating on biotech programs with a focus on cancer treatments, said on January 27 that it was shifting to defense and national security business. As part of this strategy pivot, the company will change its name to Saentra Forge.

In its new business strategy, Genenta says it will focus on acquiring private Italian businesses in the national security sector. Its targets are profitable businesses that generate about €5 million in annual EBITDA. Genenta has begun scouting for these targets. It has struck a deal that would see it acquire tactical rifles and special-forces weapon systems maker ATC, if certain performance milestones are met.

ATC holds NATO qualifications as well as authorization from Italy’s defense ministry. In 2026, ATC projects €2.0 million in EBITDA, and it expects to double this amount in 2027.

Even as Genenta pivots to defense business, it’s not abandoning its biotech programs. It plans to continue its biotech programs through partnerships.

Genenta Science SPA (NASDAQ:GNTA) was founded in 2014 and is headquartered in Milan, Italy. In the biotech space, the company’s lead drug candidate is Temferon, which is being developed as treatment for solid tumor indications. For its decision to shift to defense and national security business, Genenta said it was a response to changing market market dynamics.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None.  Follow Insider Monkey on Google News.